Two pharmaceutical companies, one Kenyan and another from India, are locked in a Sh1.4 billion legal dispute concerning rights to manufacture and distribute 45 life-saving medicines in Kenya.
The case currently in the High Court, which also implicates Kenya’s Pharmacy and Poisons Board (PPB), centres on allegations of brand infringement and regulatory failures involving the essential medicines, exposing potential regulatory gaps in Kenya’s drug oversight.